Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| §112 only | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WIECZOREK, MICHAEL P | 1 | 54.8% | +17.5% |
| GRABER, JAMES J | 1 | 46.2% | +56.1% |
| MCANANY, JOHN D | 1 | 68.0% | +51.2% |
| MARTIN, PAUL C | 1 | 42.0% | +21.7% |
| TINSLEY, BRENDAN THOMAS | 1 | 54.5% | +71.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17779567 | Method for Producing Brown Adipocytes | TINSLEY, BRENDAN THOMAS | 24d overdue |
| 18489722 | THERAPEUTIC AGENT FOR SOLID CANCERS, WHICH COMPRISES AXL INHIBITOR AS ACTIVE INGREDIENT | MCANANY, JOHN D | 22d |
| 18833460 | METHOD FOR PRODUCING MODIFIED WOODEN MATERIAL, 5-HMF RESINIFICATION SOLUTION, AND MODIFIED WOODEN MATERIAL | WIECZOREK, MICHAEL P | 23d |
| 18517402 | METHOD FOR PREPARING BROWN ADIPOCYTE | GRABER, JAMES J | 41d |
| 18276912 | METHOD FOR PRODUCING THREE-DIMENSIONAL TISSUE BODY AND METHOD FOR PROMOTING DIFFERENTIATION OF ADIPOSE-DERIVED STEM CELLS | MARTIN, PAUL C | 47d |
| Art Unit | Apps |
|---|---|
| 1712 | 1 |
| 1631 | 1 |
| 1625 | 1 |
| 1653 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833460 | METHOD FOR PRODUCING MODIFIED WOODEN MATERIAL, 5-HMF RESINIFICATION SOLUTION, AND MODIFIED WOODEN MATERIAL | WIECZOREK, MICHAEL P | 1712 | §103 | Final Rejection | 23d | Pending | Jul 26, 2024 |
| 18517402 | METHOD FOR PREPARING BROWN ADIPOCYTE | GRABER, JAMES J | 1631 | §103 | Non-Final OA | 41d | Pending | Nov 22, 2023 |
| 18489722 | THERAPEUTIC AGENT FOR SOLID CANCERS, WHICH COMPRISES AXL INHIBITOR AS ACTIVE INGREDIENT | MCANANY, JOHN D | 1625 | Other | Non-Final OA | 22d | Pending | Oct 18, 2023 |
| 18276912 | METHOD FOR PRODUCING THREE-DIMENSIONAL TISSUE BODY AND METHOD FOR PROMOTING DIFFERENTIATION OF ADIPOSE-DERIVED STEM CELLS | MARTIN, PAUL C | 1653 | §103 | Non-Final OA | 47d | Pending | Aug 11, 2023 |
| 17779567 | Method for Producing Brown Adipocytes | TINSLEY, BRENDAN THOMAS | 1634 | §112 | Final Rejection | 24d overdue | Pending | May 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial